An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia
A legfontosabb adatok
- Ki végzi
- Changzhou No.2 People's Hospital
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- Korai 1. fázis
- Résztvevők
- 9 fő, tervezett
- Kezdés
- 2024. aug. 30.
- Tervezett befejezés
- 2026. júl. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- anti-CD19 CAR NK cells (KN5501)
- A regiszteradat frissítve
- 2025. április 30.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with primary immune thrombocytopenia (ITP, an immune disorder that lowers platelets) that has not responded to several treatments. It tests CD19 CAR NK cells (KN5501).
- Életkor
- 18 to 65 years
- Nem
- Male or female
- A betegség stádiuma
- Refractory primary ITP, meaning it did not respond to treatment. The diagnosis must still be ITP on reassessment. The spleen must not be enlarged. ECOG score ≤ 1, meaning fully or nearly fully active. Heart pumping strength (LVEF) must be ≥50%.
- Korábbi kezelés
- ITP must not have responded to first-line drugs, to thrombopoietic drugs (second-line) and to rituximab. Or splenectomy (spleen removal) did not work or ITP came back after it. At least 4 weeks must have passed since the last treatment, such as radiotherapy, chemotherapy or antibody therapy.
- Biomarker vagy leletérték
- Low platelet count in at least two blood tests in a row. Bone marrow shows normal or increased megakaryocytes (platelet-making cells) with impaired maturation.
A részvétel fő kizáró okai
- Low platelets from another cause, such as other diseases, drugs, infection, pregnancy or inherited conditions
- Active infection treated with antibiotics into a vein, or such treatment within one week before the infusion
- Immune deficiency, severe heart failure (NYHA grade III or IV), epilepsy or other brain or nerve disease
- Other cancer in the past, except some cancers that were fully treated with no sign of disease left
- Pregnant or breastfeeding, or planning a pregnancy within six months
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Age: ≥ 18 years old and ≤ 65 years old, male or female, subjects voluntarily participate in this clinical study and sign the Informed Consent Form (ICF)
- Diagnosis of immune thrombocytopenia (UTP) (according to American Society of Hematology 2019 guidelines and International ITP Working Group)
- Platelet count is decreased in routine blood tests at least two consecutive times, with no obvious abnormalities in the morphology of blood cells on microscopic examination of peripheral blood smears
- Spleen is not enlarged during screening
- The morphology of bone marrow cells in subjects is characterized by increased or normal megakaryocytes with impaired maturation
- Exclude other secondary thrombocytopenia: secondary thrombocytopenia due to autoimmune diseases, thyroid disorders, lymphoproliferative disorders, myelodysplastic syndromes (MDS), aplastic anemia (AA), various malignant blood disorders, neoplastic infiltrates, chronic liver disease, hypersplenism, common variable immunodeficiency disease (CVID), infections, vaccinations, etc.; thrombocytopenia; drug-induced thrombocytopenia; homozygous thrombocytopenia; thrombocytopenia during pregnancy; congenital thrombocytopenia and pseudothrombocytopenia. Thrombocytopenia due to consumption; drug-induced thrombocytopenia; isoimmune thrombocytopenia; thrombocytopenia in pregnancy; congenital thrombocytopenia and pseudothrombocytopenia
- Subjects with refractory ITP who are refractory to first-line therapeutic agents, thrombopoietic agents in second-line therapy, and rituximab, or who have had ineffective splenectomies/postoperative recurrences, and who undergo diagnostic reassessment and remain diagnosed with ITP
- Patients with refractory ITP: refractory to first-line therapeutic agents, thrombopoietic agents in second-line therapy, and rituximab; patients diagnosed with ITP despite unsuccessful splenectomy/postoperative recurrence on diagnostic reassessment
- ECOG score ≤ 1
- Left ventricular ejection fraction (LVEF) ≥50% and no clinically significant pericardial effusion
- ≥ 4 weeks after subjects received last dose treatment (Radiotherapy, chemotherapy, monoclonal antibody therapy or other treatments)
- NRT, antimalarial monotherapy, antimalarials in combination with OCS and/or immunosuppressants, combination of OCS and/or immunosuppressants
Ki nem vehet részt
- Subjects with active infection receiving intravenous (IV) antibiotic treatment, or received intravenous (IV) antibiotic treatment within one week prior to anti-CD19 CAR NK Cell (KN5501) infusion
- Signs of herpes or varicella zoster virus infection (specifically varicella, zoster) within 12 weeks prior to screening; history of any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urinary, pulmonary, neurologic, dermatologic, psychiatric, and renal disease or other significant medical condition, other than lupus, that prevents administration of BIIB059 (as determined by the investigator)
- Subjects who have received other clinical trial treatment within 3 month
- Subjects with known severe allergic reactions, hypersensitivity, contraindication to any medications during the trial (cyclophosphamide, fludarabine, tozumabs), or subjects with a history of severe allergic reactions
- Subjects with acquired and congenital immunodeficiency diseases
- Subjects with grade III or IV heart failure (NYHA classification)
- History of epilepsy or other central nervous system (CNS) diseases
- History of severe herpes infections such as herpes encephalitis, ocular herpes, or diffuse herpes
- History of other primary malignant tumors except:; a Cured non-melanoma skin cancer by surgical excision, for example basal cell carcinoma (BCC) ; b Cured primary malignant tumors, such as cervical cancer, superficial bladder cancer, breast cancer
- Females who are pregnant, lactating, or planning a pregnancy within six months
- History or current diagnosis of clinically significant non-ITP-induced thrombocytopenia
- Any situation judged by the investigators that may increase the risk of the subjects or interfere with the clinical trial outcome
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 65 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19 CAR NK cells (KN5501) in patients with refractory immune thrombocytopenia. 9 patients are planned to be enrolled in the dose-escalation trial (9×10\^9 cells, 13.5×10\^9 cells). The primary objective of the study is to evaluation of the safety and feasibility of KN5501 for the treatment of relapsed/refractory B-cell related autoimmune diseases. The secondary objective is to evaluate evaluation of KN5501 for the treatment of refractory immune thrombocytopenia. The exploratory objective is to evaluate expansion, persistence and ability to deplete CD19 positive B cells of KN5501 in patients with refractory immune thrombocytopenia.
A vizsgálat csoportja
- anti-CD19 CAR NK cellsA vizsgált kezelés
Kezelés: anti-CD19 CAR NK cells (KN5501)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cell Injections for the Treatment of Refractory Primary Immune Thrombocytopenia
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT06337474: ki vehet részt
- A regiszteradat frissítve
- 2025. április 30.